Gene startup 23andme casts eyes abroad after U.S. regulatory hurdle

[Reuters] – Home genetics startup 23andme is forging ahead with plans to sell its full-fledged test kit – just not in the United States. Late last year, the company agreed to stop selling its $99 DNA test until it obtained marketing authorization from th more

View todays social media effects on GOOGL

View the latest stocks trending across Twitter. Click to view dashboard

See who Google is hiring next, click here to view